Targeting Breast Cancer Stem Cells

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2023 Jan 12

PMID 36632469

Authors

Lu Zhang

Wenmin Chen

Suling Liu

Ceshi Chen

Affiliations

Soon will be listed here.

Abstract

The potential roles of breast cancer stem cells (BCSCs) in tumor initiation and recurrence have been recognized for many decades. Due to their strong capacity for self-renewal and differentiation, BCSCs are the major reasons for poor clinical outcomes and low therapeutic response. Several hypotheses on the origin of cancer stem cells have been proposed, including critical gene mutations in stem cells, dedifferentiation of somatic cells, and cell plasticity remodeling by epithelial-mesenchymal transition (EMT) and the tumor microenvironment. Moreover, the tumor microenvironment, including cellular components and cytokines, modulates the self-renewal and therapeutic resistance of BCSCs. Small molecules, antibodies, and chimeric antigen receptor (CAR)-T cells targeting BCSCs have been developed, and their applications in combination with conventional therapies are undergoing clinical trials. In this review, we focus on the features of BCSCs, emphasize the major factors and tumor environment that regulate the stemness of BCSCs, and discuss potential BCSC-targeting therapies.

Citing Articles

Effects of 5-azacytidine and N6-methyladenosine combination on apoptosis and stemness in human breast cancer stem cells.

Mukhtarova G, Angin M, Caner A, Gunduz C Mol Biol Rep. 2025; 52(1):292.

PMID: 40055211 DOI: 10.1007/s11033-025-10398-2.

Key roles of ubiquitination in regulating critical regulators of cancer stem cell functionality.

Guo Q, Qin H, Chen Z, Zhang W, Zheng L, Qin T Genes Dis. 2025; 12(3):101311.

PMID: 40034124 PMC: 11875185. DOI: 10.1016/j.gendis.2024.101311.

Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives.

Alalhareth I, Alyami S, Alshareef A, Ajeibi A, Al Munjem M, Elfifi A Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006021 PMC: 11858621. DOI: 10.3390/ph18020207.

Adiponectin Influences the Behavior of Stem Cells in Hormone-Resistant Breast Cancer.

Naimo G, Forestiero M, Giordano F, Leonetti A, Gelsomino L, Panno M Cells. 2025; 14(4).

PMID: 39996758 PMC: 11853953. DOI: 10.3390/cells14040286.

TFF3 facilitates dormancy of anti-estrogen treated ER+ mammary carcinoma.

Chen S, Zhang X, Basappa B, Zhu T, Pandey V, Lobie P Commun Med (Lond). 2025; 5(1):45.

PMID: 39984660 PMC: 11845601. DOI: 10.1038/s43856-024-00710-9.

References

De Francesco E, Ozsvari B, Sotgia F, Lisanti M . Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine). Front Oncol. 2019; 9:615. PMC: 6692486. DOI: 10.3389/fonc.2019.00615. View

Yi H, Wu M, Zhang Q, Lu L, Yao H, Chen S . Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells. J Cancer. 2020; 11(13):3713-3716. PMC: 7171481. DOI: 10.7150/jca.39265. View

Liu S, Lee J, Jie C, Park M, Iwakura Y, Patel Y . HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance. Cancer Res. 2018; 78(8):2040-2051. PMC: 5899630. DOI: 10.1158/0008-5472.CAN-17-2761. View

Cai P, Xiao Z, Pan T, Wen X, Cao J, Ouyang B . Lx2-32c inhibits the formation of mammosphere from MDA-MB-231 cells and induces apoptosis involving in down-regulating FoxM1. Biomed Pharmacother. 2018; 102:1176-1181. DOI: 10.1016/j.biopha.2018.03.143. View

Brock C, Hebert K, Artiles M, Wright M, Cheng T, Windsor G . A Role for Adipocytes and Adipose Stem Cells in the Breast Tumor Microenvironment and Regenerative Medicine. Front Physiol. 2021; 12:751239. PMC: 8667576. DOI: 10.3389/fphys.2021.751239. View

Lee K, Kuo Y, Ho Y, Huang Y . Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. Cancers (Basel). 2019; 11(9). PMC: 6769912. DOI: 10.3390/cancers11091334. View

Turunen S, von Nandelstadh P, Ohman T, Gucciardo E, Seashore-Ludlow B, Martins B . FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis. Cell Death Differ. 2019; 26(12):2577-2593. PMC: 7224384. DOI: 10.1038/s41418-019-0321-x. View

Wang Y, Jia A, Bi Y, Wang Y, Yang Q, Cao Y . Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. Cancers (Basel). 2020; 12(9). PMC: 7564060. DOI: 10.3390/cancers12092626. View

Flynn A, Calhoun B, Sharma A, Chang J, Almasan A, Schiemann W . Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nat Commun. 2019; 10(1):3668. PMC: 6694140. DOI: 10.1038/s41467-019-11640-9. View

10.

Luga V, Zhang L, Viloria-Petit A, Ogunjimi A, Inanlou M, Chiu E . Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151(7):1542-56. DOI: 10.1016/j.cell.2012.11.024. View

11.

Merritt N, Garcia K, Rajendran D, Lin Z, Zhang X, Mitchell K . TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex. Elife. 2021; 10. PMC: 8143797. DOI: 10.7554/eLife.62857. View

12.

Watson C . How should we define mammary stem cells?. Trends Cell Biol. 2021; 31(8):621-627. DOI: 10.1016/j.tcb.2021.03.012. View

13.

Tanas M, Ma S, Jadaan F, Ng C, Weigelt B, Reis-Filho J . Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein. Oncogene. 2015; 35(7):929-38. PMC: 4983459. DOI: 10.1038/onc.2015.148. View

14.

Chen W, Qin Y, Wang D, Zhou L, Liu Y, Chen S . CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol. 2018; 16(7):e2005869. PMC: 6082578. DOI: 10.1371/journal.pbio.2005869. View

15.

Oh E, Kim Y, An H, Sung D, Cho T, Farrand L . Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. Int J Cancer. 2018; 143(8):1978-1993. DOI: 10.1002/ijc.31585. View

16.

Ryoo I, Choi B, Ku S, Kwak M . High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: Implications for cancer stem cell resistance. Redox Biol. 2018; 17:246-258. PMC: 6006726. DOI: 10.1016/j.redox.2018.04.015. View

17.

Raghavan S, Mehta P, Xie Y, Lei Y, Mehta G . Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. J Immunother Cancer. 2019; 7(1):190. PMC: 6642605. DOI: 10.1186/s40425-019-0666-1. View

18.

Devereaux S, Linch D, Gribben J, McMillan A, Patterson K, Goldstone A . GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease. Bone Marrow Transplant. 1989; 4(1):49-54. View

19.

Ding A, Zheng S, Huang X, Xing T, Wu G, Sun H . Current Perspective in the Discovery of Anti-aging Agents from Natural Products. Nat Prod Bioprospect. 2017; 7(5):335-404. PMC: 5655361. DOI: 10.1007/s13659-017-0135-9. View

20.

Liu Y, Zheng C, Huang Y, He M, Xu W, Li B . Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm (2020). 2021; 2(3):315-340. PMC: 8554658. DOI: 10.1002/mco2.55. View